• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Blog Home
  • Topics
    • Keystone Press Releases
    • Politics and Government
    • Legislation
    • Nevada News
    • Tourism & Gaming
    • Rural Nevada
    • Business
    • Opinion
  • Membership
  • Contact Us
  • About Keystone Nevada

Keystone Nevada Korner

Welcome to The Keystone Korner The Official Blog of Keystone Nevada

Home » Drug Prices Haven’t Been Going Up

Drug Prices Haven’t Been Going Up

December 26, 2021 by Pauline Lee

The myth that they have drives Biden’s proposals for price controls, which would throttle innovation.

by Joel Zinberg, The Wall Street Journal, December 26, 2021

Build Back Better may be dead, but its proposed drug price controls will likely reappear: negotiating prices for high-cost drugs in Medicare and price controls for most drugs limiting price increases to the annual inflation rate.

President Biden insists such controls are needed because pharmaceutical companies are “jacking up prices on a range of medicines.” He promises “to end the days when drug companies could increase their prices with no oversight and no accountability.” Yet while inflation has skyrocketed under Mr. Biden, drug prices are lower than when he took office. As the consumer-price index over the past year rose 6.8%, the largest increase in 39 years, prescription-drug prices fell 0.3%.

Mr. Biden and other pharmaceutical critics have mistakenly focused on increases in the list prices set by companies. But the actual prices consumers pay, after various discounts and rebates, are considerably lower than list prices, and changes in the two measures differ substantially. Insulin, with large increases in list prices over the past few decades, has become the poster child for unreasonable price increases. Yet net prices have increased much more slowly or not at all.

The best measure is the consumer-price index for prescription drugs, or CPI-Rx, which measures price changes in a large basket of drugs over time, accounting for discounts and most rebates. Another strength of the CPI-Rx is that it accounts for price declines that occur when consumers substitute cheaper generic versions for brand-name drugs. Too often, Mr. Biden and others focus on a few high-priced drugs and fail to consider the entire market.

Prices for brand-name prescription drugs are higher in the U.S. than in other countries. But U.S. regulatory, legal and incentive structures encourage aggressive price competition and switching from branded drugs to generics. As a result, Americans use more generics (accounting for 9 out of 10 prescriptions) and pay less for them (16% lower on average) than in other developed countries. Nearly all European countries impose price controls on generics, which results in delayed market entry and availability, less competition and higher prices.

CPI-Rx has been negative for much of the past three years. The decline stems largely from increased drug approvals by the Food and Drug Administration since 2017. When new brand-name drugs enter the market, they compete with other drugs that treat the same condition. When generic versions are approved, prices fall rapidly as patients switch, especially as multiple generic versions enter the market.

An analysis of per-unit prices of 27 types of insulin by GoodRx, a healthcare company that tracks drug prices and provides discount coupons, found that overall retail prices declined by nearly 6% since 2019 because of recent approvals of generics and biosimilar drugs.

Mr. Biden’s proposed price controls aren’t merely superfluous. They risk lowering the number of innovative new drugs that improve health and eventually become the low-priced generics used by most Americans. Pharmaceutical companies invest in research in anticipation of future profit. Unlike most industries, they primarily finance it out of current revenues. University of Chicago economist Tomas Philipson estimates Mr. Biden’s proposed price controls could lead to a 29% to 60% reduction in research and development, resulting in 167 to 342 fewer new drug approvals over the next 20 years.

The rapid development of Covid vaccines and therapeutics confirmed the importance of preserving our innovative pharmaceutical industry. The pandemic also confirmed that the FDA is capable of safely shortening approval times. Speeding approvals and increasing competition are a far better prescription than price controls that would strangle future innovation.

Dr. Zinberg is senior fellow at the Competitive Enterprise Institute, director of Paragon Health Institute’s Public Health and American Well-being Initiative, and associate clinical professor of surgery at the Icahn Mount Sinai School of Medicine. He was general counsel and senior economist at the White House Council of Economic Advisers from 2017 to 2019.

Filed Under: Opinion Tagged With: consumer-price index, drug price controls, Drug prices, pharmaceutical critics

Primary Sidebar

Connect with Us

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
Bootleg Bistro
Bootleg Bistro Ad
SLLC_Keystone_Blog-Ad_300x500_10%-Off-Repairs_05.19.21
CIOServices Ad 300x500-100
BRH Keystone Ad JPEG
Willow_Manor
Keystone Corporation Nevada

News Topics

  • Keystone Press Releases
  • Politics and Government
  • Legislation
  • Nevada News
  • Tourism & Gaming
  • Rural Nevada
  • Business
  • Opinion

Rural Nevada

Winnemucca braces for massive lithium mine

September 18, 2023 By Courtney Holland

By Ray Hagar, Nevada Newsmakers, September 18, 2023 Winnemucca, a town of more than 8,600 residents off Interstate 80 in Northern Nevada, is proud … [Read More...] about Winnemucca braces for massive lithium mine

Weather may have slowed January sales

April 8, 2023 By Courtney Holland

By The Record Courier Staff, April 4, 2023 For the third month in a row, Douglas County merchants reported a decrease in taxable sales, though not … [Read More...] about Weather may have slowed January sales

30 new projects in Pahrump: Arby’s, Chipotle, Midas Muffler, 3 convenient stores & more

March 29, 2023 By Courtney Holland

By Robin Hebrock, Pahrump Valley Times, March 28, 2023 Business is booming in the Pahrump Valley, with dozens of new companies looking to bring … [Read More...] about 30 new projects in Pahrump: Arby’s, Chipotle, Midas Muffler, 3 convenient stores & more

UPS and AVK America plan to expand in Douglas County

March 19, 2023 By Courtney Holland

Staff Reports for The Record Courier, March 17, 2023 United Parcel Service plans to build a new 168,000 square foot building in Douglas County, … [Read More...] about UPS and AVK America plan to expand in Douglas County

Opinion

EDITORIAL: Never Never Land for California regulators

September 25, 2023 By Courtney Holland

By the Las Vegas Review-Journal Editorial Board, September 24, 2023 It’s shocking, but California’s efforts to force-feed electric vehicles to its … [Read More...] about EDITORIAL: Never Never Land for California regulators

OPINION: American mining needs Gen Z

September 25, 2023 By Courtney Holland

By Rich Nolan, Reno Gazette Journal, September 18, 2023 By 2030, Gen Z will be 30 percent of the American workforce. This tech-savvy generation has … [Read More...] about OPINION: American mining needs Gen Z

OPINION: DExit to the desert: Why I left Delaware for Nevada

September 25, 2023 By Courtney Holland

By Phil Shawn, The Nevada Independent, September 15th, 2023 Some 80 years ago, visionaries saw a dusty military outpost in the middle of the Nevada … [Read More...] about OPINION: DExit to the desert: Why I left Delaware for Nevada

Tags

Adam Laxalt Biden Administration Business Business Columns Casinos & Gaming Catherine Cortez Masto Clark County Clark County School District economy Editorials Education Elon Musk employment Gov. Joe Lombardo Gov. Steve Sisolak Governor's Office of Economic Development (GOED) Housing inflation Inside Gaming Joe Lombardo las vegas Local Local Las Vegas Local Nevada mc-business mc-local mc-news mc-opinion Nevada News North Las Vegas NPRI Opinion Opinion Columns PAID Politics and Government Real Estate Insider Roe v. Wade school choice Sen. Catherine Cortez Masto small businesses Sports Tesla tourism Victor Joecks

Footer

Copyright © 2023 · Keystone Corporation - All Rights Reserved · Log in
Privacy Policy
By accessing this site, you are agreeing to our Terms of Use

The views, opinions and conclusions expressed by the authors of any article or post on the Keystone Korner are those of the author and do not necessarily reflect the opinions of Keystone Corporation or its officers and board members. Moreover, any reference to a person, party, product or entity does not constitute an endorsement or recommendation by Keystone Corporation or its officers and board members.